All In Biotech

Drug Trial Radar · NCT07816237

A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria, PNH

Interventions

  • VSA012Drug

    VSA012 Injection

  • Eculizumab (Soliris®)Drug

    Eculizumab injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with sustained hemoglobin levels ≥ 120 g/L among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).Time frame: between Week 2 and Week 26

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Jilin

    Jilin City, Changchun, China

  • Quanzhou

    Quanzhou, Fujian, China

  • Guangzhou

    Guangzhou, Guangdong, China

  • Nanning

    Nanning, Guangxi, China

  • Ha'erbin

    Harbin, Heilongjiang, China

  • Zhengzhou

    Zhengzhou, Henan, China

  • Wuhan

    Wuhan, Hubei, China

  • Changsha

    Changsha, Hunan, China

  • Nantong

    Nantong, Jiangsu, China

  • Xi'an

    Xi’an, Shanxi, China

  • Chengdu

    Chengdu, Sichuan, China

  • Institute of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.